Application scope of total bile acid determination kit

The total bile acid determination kit is mainly used for quantitative determination of total bile acid (TBA) concentration in human serum or plasma samples in vitro. Its application scope covers a wide range of clinical diagnosis, disease monitoring, and scientific research fields, as follows:

1. Clinical diagnosis and disease monitoring

Liver disease diagnosis

Total bile acid (TBA) is a key indicator of liver synthesis, secretion, and metabolism, and its level changes can directly reflect liver cell function.

Application scenarios:

Acute and chronic hepatitis: TBA levels are significantly elevated, earlier than transaminase changes, and are sensitive indicators of early liver injury.

. Cirrhosis: As liver fibrosis worsens, TBA continues to increase and is positively correlated with the severity of the disease. Primary liver cancer: Tumor cells interfere with bile acid metabolism, leading to abnormal TBA, which assists in tumor diagnosis and prognosis evaluation. Alcoholic liver disease: Long term drinkers have elevated TBA levels, reflecting hepatic steatosis and inflammatory damage.

Monitoring of biliary system diseases

When there is biliary obstruction (such as gallstones, bile duct cancer), bile excretion is obstructed, TBA refluxes into the bloodstream, and the level significantly increases.

.

Application value: By dynamically monitoring changes in TBA, the degree of biliary obstruction and treatment effectiveness can be evaluated.

.

Screening for intrahepatic cholestasis of pregnancy (ICP)

Elevated TBA levels in pregnant women are the core feature of ICP, which may lead to complications such as fetal distress and premature birth.

. Clinical significance: Regular detection of TBA can detect ICP early and intervene promptly to improve pregnancy outcomes.

II. Applicable departments and detection scenarios

Infection department

is used for liver injury assessment and efficacy monitoring of viral hepatitis (such as hepatitis A, hepatitis B and hepatitis C). Obstetrics and Gynecology: ICP screening during pregnancy to prevent adverse fetal outcomes through TBA testing.

Physical Examination Department

TBA testing during routine physical examinations can assist in detecting asymptomatic liver injury (such as fatty liver and drug-induced liver disease).

.

Hepatobiliary Surgery

Preoperative evaluation of liver function in patients with biliary obstruction, and postoperative monitoring of TBA recovery.

. Early diagnosis and disease tracking of pediatric liver diseases (such as congenital biliary atresia and metabolic liver disease).

Gastroenterology

Long term management of chronic liver diseases such as autoimmune hepatitis and primary biliary cholangitis.

. Oncology Department: Treatment response assessment and prognosis prediction for liver cancer patients.

III. Technical Features and Advantages

High Sensitivity and Accuracy

Using enzyme cycling method (EC method) or vanadate oxidation method, amplifying the signal through multiple enzymatic reactions, TBA concentration as low as 5 μ mol/L can be detected.

. The linear range is wide (5-200 μ mol/L), meeting clinical and scientific research needs.

Strong anti-interference ability

In the presence of interfering substances such as bilirubin and hemoglobin, the detection stability can still be maintained, and the results are reliable.

.

Easy to operate

Liquid dual reagent design, suitable for fully automatic biochemical analyzers (such as Mindray, Hitachi, Toshiba, etc.), achieving high-throughput detection.

. The stability of the reagent bottle opening reaches 30 days, reducing waste.

Interpretation of Results Standardization

Normal reference range ≤ 10 μ mol/L, exceeding the standard indicates abnormalities in the liver and gallbladder system, and requires comprehensive diagnosis in combination with other examinations.

.

Fourth, Scientific Research Application

Research on the Mechanism of Liver Disease

Exploring the Molecular Mechanisms of Liver Cell Injury and Abnormal Bile Acid Metabolism through Changes in TBA Levels.

.

Drug efficacy evaluation

Evaluate the regulatory effect of hepatoprotective drugs (such as ursodeoxycholic acid) on TBA and optimize treatment plans.

.

Development of disease biomarkers

Combining other biomarkers (such as ALT, AST, GGT) to construct a liver disease diagnostic model and improve early diagnosis rates.

.